Journal
ADVANCES IN THERAPY
Volume 38, Issue 10, Pages 5087-5097Publisher
SPRINGER
DOI: 10.1007/s12325-021-01781-z
Keywords
Migraine; acute; CGRP; 5-HT1F; Rimegepant; Ubrogepant; Lasmiditan; Triptan; Eligibility; Budget impact; Model
Funding
- Biohaven Pharmaceuticals, Inc.
Ask authors/readers for more resources
Current standards of care for migraine management may not adequately address the disability associated with the condition. This study aimed to estimate the potential use of new acute therapies for migraine, with findings suggesting that 15-25% of individuals with migraine may be eligible for these new treatments. The development of a conceptual framework offers a tool for assessing the eligible patient population and associated costs of these new therapies.
Introduction Migraine is associated with considerable disability for patients not adequately managed with current standards of care. New acute therapies may offer relief for this population of patients; however, population size and associated potential costs of new therapies are unclear. In this study, a conceptual framework was developed to estimate anticipated use of new acute therapies. Methods Targeted literature review (TLR) was conducted to identify factors affecting access to migraine-specific acute therapies, and characteristics of individuals who would be eligible for new acute therapies. Findings from the TLR were combined to create a framework for estimating the size of the eligible patient population. This framework was used to calculate two estimates of the eligible patient population by applying parameters (i) identified in the TLR and (ii) from a recent budget-impact analysis (BIA). Results The primary factors affecting access to migraine-specific acute therapies identified in the TLR were consulting a healthcare professional for headache, receiving a migraine diagnosis, and receiving a prescription for migraine-specific treatment. Characteristics of individuals likely to use new acute therapies reflected in the TLR were contraindication to triptans, or failure to respond to/tolerate at least two oral triptans. Application of the framework suggested that 15-25% of individuals with migraine would be eligible for new acute therapies. Conclusion A limited number of patients currently use migraine-specific acute therapies. Among such patients, a significant proportion do not have adequate symptom control. Accordingly, a minority of individuals with migraine may be expected to use new acute therapies. The framework developed in this study is intended to facilitate estimating the eligible patient population in assessments of costs of new acute therapies. Such assessments should also consider recommendations that patients have access to multiple types of acute therapies, which may yield savings from reduced medication-overuse headache (MOH), progression to chronic migraine, and urgent-care costs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available